share_log

Earnings Are Growing at 3SBio (HKG:1530) but Shareholders Still Don't Like Its Prospects

Earnings Are Growing at 3SBio (HKG:1530) but Shareholders Still Don't Like Its Prospects

3sBio(HKG: 1530)的收益正在增长,但股东们仍然不喜欢它的前景
Simply Wall St ·  2023/11/14 09:23

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But the main game is to find enough winners to more than offset the losers At this point some shareholders may be questioning their investment in 3SBio Inc. (HKG:1530), since the last five years saw the share price fall 45%. On top of that, the share price is down 8.3% in the last week.

为了证明选择个股的努力是合理的,值得努力击败市场指数基金的回报。但主要的游戏是找到足够的赢家来抵消输家。此时,一些股东可能会质疑他们对3sBio Inc.(HKG: 1530)的投资,因为在过去五年中,股价下跌了45%。最重要的是,上周股价下跌了8.3%。

Given the past week has been tough on shareholders, let's investigate the fundamentals and see what we can learn.

鉴于过去一周对股东来说很艰难,让我们调查一下基本面,看看我们能学到什么。

Check out our latest analysis for 3SBio

查看我们对 3sBio 的最新分析

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

在他的文章中 格雷厄姆和多兹维尔的超级投资者 沃伦·巴菲特描述了股价如何并不总是合理地反映企业的价值。通过比较每股收益(EPS)和一段时间内的股价变化,我们可以了解投资者对公司的态度是如何随着时间的推移而变化的。

During the unfortunate half decade during which the share price slipped, 3SBio actually saw its earnings per share (EPS) improve by 14% per year. Given the share price reaction, one might suspect that EPS is not a good guide to the business performance during the period (perhaps due to a one-off loss or gain). Alternatively, growth expectations may have been unreasonable in the past.

在股价下滑的不幸五年中,3sBio的每股收益(EPS)实际上每年增长14%。鉴于股价反应,人们可能会怀疑每股收益并不能很好地指导该期间的业务表现(可能是由于一次性亏损或收益)。或者,过去的增长预期可能不合理。

Because of the sharp contrast between the EPS growth rate and the share price growth, we're inclined to look to other metrics to understand the changing market sentiment around the stock.

由于每股收益增长率与股价增长形成鲜明对比,我们倾向于参考其他指标来了解围绕该股的市场情绪变化。

We don't think that the 1.4% is big factor in the share price, since it's quite small, as dividends go. In contrast to the share price, revenue has actually increased by 10% a year in the five year period. A more detailed examination of the revenue and earnings may or may not explain why the share price languishes; there could be an opportunity.

我们认为1.4%并不是影响股价的重要因素,因为随着股息的增加,股价相当小。与股价形成鲜明对比的是,在过去的五年中,收入实际上每年增长10%。对收入和收益进行更详细的审查可能会也可能无法解释股价下跌的原因;可能有机会。

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

下图描述了收入和收入随时间推移而发生的变化(点击图片即可显示确切的数值)。

earnings-and-revenue-growth
SEHK:1530 Earnings and Revenue Growth November 13th 2023
香港交易所:1530 2023年11月13日收益和收入增长

We know that 3SBio has improved its bottom line lately, but what does the future have in store? So we recommend checking out this free report showing consensus forecasts

我们知道3sBio最近提高了利润,但是未来会发生什么?因此,我们建议您查看这份显示共识预测的免费报告

What About Dividends?

分红呢?

When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. As it happens, 3SBio's TSR for the last 5 years was -42%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments!

在考虑投资回报时,重要的是要考虑两者之间的区别 股东总回报 (TSR) 和 股价回报。股东总回报率是一种回报计算方法,它考虑了现金分红的价值(假设收到的任何股息已被再投资)以及任何贴现资本筹集和分拆的计算价值。可以公平地说,股东总回报率为支付股息的股票提供了更完整的画面。碰巧的是,3sBio在过去5年的股东总回报率为-42%,超过了前面提到的股价回报率。这在很大程度上是其股息支付的结果!

A Different Perspective

不同的视角

While the broader market gained around 3.2% in the last year, 3SBio shareholders lost 6.8% (even including dividends). Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. However, the loss over the last year isn't as bad as the 7% per annum loss investors have suffered over the last half decade. We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize. Before deciding if you like the current share price, check how 3SBio scores on these 3 valuation metrics.

尽管去年整个市场上涨了约3.2%,但3sBio的股东却下跌了6.8%(甚至包括股息)。即使是优质股票的股价有时也会下跌,但我们希望看到企业的基本指标有所改善,然后才会变得过于感兴趣。但是,去年的亏损并不像投资者在过去五年中遭受的7%的年亏损那么严重。在认为股价将稳定之前,我们希望获得明确的信息,表明公司将增长。在决定您是否喜欢当前的股价之前,请查看3sBio在这三个估值指标上的得分。

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

如果你想与管理层一起购买股票,那么你可能会喜欢这份免费的公司名单。(提示:业内人士一直在购买它们)。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Hong Kong exchanges.

请注意,本文引用的市场回报反映了目前在香港交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发